Obecabtagene autoleucel (obe-cel)

BIOLOGICAL2 trials

Sponsors

Autolus Limited

Conditions

Progressive Multiple SclerosisSystemic Lupus Erythematosus

Phase 1

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

Active, not recruitingNCT06333483

Autolus LimitedSystemic Lupus Erythematosus

Start: 2024-02-02End: 2027-09-01Updated: 2026-07-31

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

RecruitingNCT07139743

Autolus LimitedProgressive Multiple Sclerosis

Start: 2025-08-04End: 2029-08-15Target: 18Updated: 2026-03-23

Related Papers

Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results

Blood2025-11-03